Loading your page…
Marketing-authorisation holder
24 medicines in 5 countries, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
24 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| DACARBAZINA LIPOMEDPolvere per soluzione iniettabile/per infusione | Dacarbazine | Italy | Authorised | |
| Deferiprone Lipomed | Deferiprone | EU (EMA) | Authorised | 2018 |
| DEFERIPRONE LIPOMEDCompressa rivestita con film | Deferiprone | Italy | Authorised | |
| Deferiprone Lipomed 500 mg filmomhulde tablettenFilmomhulde tablet | Deferiprone | Netherlands | Authorised | 2018 |
| Jayempi | Azathioprine | EU (EMA) | Authorised | 2021 |
| JAYEMPISospensione orale | Azathioprine | Italy | Authorised | |
| Jayempi 10 mg/ml, orale suspensieSuspensie voor oraal gebruik | Azathioprine | Netherlands | Authorised | 2021 |
| LITAKSoluzione iniettabile | Cladribine | Italy | Authorised | |
| Litak | Cladribine | EU (EMA) | Authorised | 2004 |
| LITAK 2 mg/ml SOLUCION INYECTABLE2 mg · Solución inyectable | Cladribine | Spain | Marketed | 2007 |
| LITAK 2 mg/ml SOLUCION INYECTABLE2 mg · Solución inyectable | Cladribine | Spain | Marketed | 2007 |
| Litak, oplossing voor injectie 2 mg/mlOplossing voor injectie | Cladribine | Netherlands | Authorised | 2004 |
| Qaialdo | Spironolactone | EU (EMA) | Authorised | 2023 |
| QAIALDOSospensione orale | Spironolactone | Italy | Authorised | |
| Qaialdo 10 mg/ml orale suspensieSuspensie voor oraal gebruik | Spironolactone | Netherlands | Authorised | 2023 |
| Thalidomide Lipomed | Thalidomide | EU (EMA) | Authorised | 2022 |
| Thalidomide Lipomed 100 mg, filmomhulde tablettenFilmomhulde tablet | Thalidomide | Netherlands | Authorised | 2022 |
| XALUPRINESospensione orale | Mercaptopurine | Italy | Authorised | |
| Xaluprine 100 mg/5 ml, suspensie voor oraal gebruikSuspensie voor oraal gebruik | Mercaptopurine | Netherlands | Authorised | 2012 |
| Xaluprine (previously Mercaptopurine Nova Laboratories) | Mercaptopurine | EU (EMA) | Authorised | 2012 |
| Xromi | Hydroxycarbamide | EU (EMA) | Authorised | 2019 |
| Xromi 100 mg/ml drankDrank | Hydroxycarbamide | Netherlands | Authorised | 2019 |
| DACARBAZINA LIPOMED 200 mg200 mg · Pulb. pt. sol. inj. sau perf. | Dacarbazine | Romania | unknown | |
| LITAK 2 mg/ml2mg/ml · Sol. inj. | Cladribine | Romania | unknown |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 7 | 7 | 0 | CompaniesAll medicines |
| Netherlands | 7 | 7 | 0 | CompaniesAll medicines |
| Italy | 6 | 6 | 0 | CompaniesAll medicines |
| Spain | 2 | 2 | 0 | CompaniesAll medicines |
| Romania | 2 | 0 | 2 | CompaniesAll medicines |
Also in the registers of United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
